anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 238,321-238,350
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

238,321-238,350 of 303,780

filter-aware
08
The slide combines a problem statement (clinical unmet need) with a market sizing chart.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
09
Includes clinical trial timeline diagram and outcome tables.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
10
The table uses blue highlighting to emphasize the higher severity metrics in the EBO Ph 2 group.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
LSM = Least squares mean. Data points include two LSM changes and two p-values.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
The chart highlights a statistically significant improvement (p=0.036) at month 6.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide presents TEAE (Treatment-emergent adverse events) and SAE (Serious adverse events) data.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
Focuses on regulatory strategy and clinical trial progression for EBO-301.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
16
The slide presents three line charts (A, B, C) comparing PBS, IMI (Imipenem), and two doses of EBO (EBO25, EBO50) over 4 weeks.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
17
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
18
Includes a map showing global distribution and a specific callout for US endemicity.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
19
The slide uses a central hub-and-spoke style diagram to connect funding sources with market potential.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
20
The chart shows Log10 CFU counts in lungs for various treatment groups compared to untreated control.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
23
Includes a disease progression timeline diagram on the right.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram to break down global prevalence numbers.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a dot map to visualize geographic distribution of infections.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
26
Includes chemical structure of the drug candidate.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
27
The chart demonstrates superior efficacy of the lead compound over existing treatments (Benznidazole and E1224) in a model that mirrors human clinical outcomes.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
28
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
30
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
31
The slide uses a hub-and-spoke diagram to connect Boron to various therapeutic areas, specifically focusing on oncology applications.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
32
The slide uses a hub-and-spoke diagram to connect the central Boron element to four therapeutic areas, then maps those to two specific drug development programs.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
33
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
34
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
35
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
36
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
Hagerty | Investor Presentation Deck | 22 slidesHagerty | Investor Presentation Deck | 22 slides · Hagerty
Pitch deck Investor relations 1 hit
02
Hagerty | Investor Presentation Deck | 22 slidesHagerty | Investor Presentation Deck | 22 slides · Hagerty
Pitch deck Investor relations 1 hit
03
The slide uses a split layout with a financial performance table on the left and a lifestyle image on the right.Hagerty | Investor Presentation Deck | 22 slides · Hagerty
Pitch deck Investor relations Beat · Problem1 hit
04
The slide uses a split-screen layout with a thematic car image on the left and financial highlights on the right.Hagerty | Investor Presentation Deck | 22 slides · Hagerty
Pitch deck Investor relations Beat · Problem1 hit